Researchers at University of California San Diego School of Medicine’s Center for Medicinal Cannabis Research are seeking participants as they prepare to begin a set of clinical trials exploring the effectiveness of cannabidiol (CBD) and tetrahydrocannabinol (THC) in treating symptoms of severe autism, anorexia nervosa, essential tremor, and early psychosis.
In Phase I of the first-of-its-kind essential tremor study, which is scheduled for early 2019, 16 participants will receive an oral 20:1 CBD to THC formulation before tapering off to a washout period and beginning Phase II.
Essential tremor is a nervous system disorder that affects an estimated 10 million Americans and is currently treated with medications initially formulated for seizures and high blood pressure.
The autism study will launch in 2020 and consist of 30 children between the ages of eight and twelve who are in overall good health and have been diagnosed with moderate to severe autism.
For the first stage of the trial, half of the children will receive an oral dose of CBD while the others will receive a placebo. The groups will switch CBD and placebo doses for the second stage.
The anorexia nervosa study will involve ten adult participants who are over the age of 18 and have a confirmed diagnosis of the condition.
The goal of the study, which will begin in 2020, is to determine if CBD is safe and tolerable and how well it helps relieve symptoms, including anxiety.
The study on early psychosis seeks to determine how well CBD can reduce symptoms and improve overall cognition as well as examine its effect on biological response to stress and antipsychotic medication-induced eating behaviors.
Seventy-eight adult participants in the trial who have been diagnosed with first episode psychosis and are currently taking antipsychotic medication will augment their regimen for six weeks with randomized doses of CBD or placebos.
To Participate:
Essential Tremor Study
Anorexia Nervosa Study
Severe Autism Study
Early Psychosis Study
